

**Responses to Tetanus and Meningococcal Vaccines in Patients with AA Treated with
Ritlecitinib**

Rahmat Ishowo-Adejumo,¹ Agnieszka Zareba,¹ Dalia Wajsbrod,² Robert Wolk³

¹Pfizer Inc, Collegeville, PA, USA; ²Pfizer Inc, New York, NY, USA; ³Pfizer Inc, Groton, CT, USA

Corresponding author:

Rahmat Ishowo-Adejumo

500 Arcola Rd

Collegeville, PA 19426

Rahmat.Adejumo@pfizer.com

Table S1. Disposition table

Participants, n (%)	Tdap vaccination (N=17)	MenACWY-CRM vaccination (n=13)	Total^a
Discontinued	1 (5.9)	1 (7.7)	1 (5.9)
Withdrawal by participant	1 (5.9)	1 (7.7)	1 (5.9)
Completed ^b	16 (94.1)	12 (92.3)	16 (94.1)

^a Participants who received both Tdap and Meningococcal ACWY are only counted once.

^b Participants who completed the follow-up Day 31 visit of vaccine sub-study.

MenACWY-CRM, meningococcal groups A, C, Y, and W-135 oligosaccharide diphtheria CRM₁₉₇ conjugate vaccine; Tdap, tetanus and diphtheria toxoids and acellular pertussis vaccine.